DNA Modification Methylases
"DNA Modification Methylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the host-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognized by the restriction endonucleases of similar specificity and destroyed by cleavage. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
Descriptor ID |
D015254
|
MeSH Number(s) |
D08.811.150.240 D08.811.913.555.500.350
|
Concept/Terms |
DNA Modification Methylases- DNA Modification Methylases
- Methylases, DNA Modification
- Modification Methylases, DNA
- Modification Methylases
- Methylases, Modification
- DNA Modification Methyltransferases
- Methyltransferases, DNA Modification
- Modification Methyltransferases, DNA
|
Below are MeSH descriptors whose meaning is more general than "DNA Modification Methylases".
Below are MeSH descriptors whose meaning is more specific than "DNA Modification Methylases".
This graph shows the total number of publications written about "DNA Modification Methylases" by people in this website by year, and whether "DNA Modification Methylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Modification Methylases" by people in Profiles.
-
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Int J Mol Sci. 2023 Apr 27; 24(9).
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-192.
-
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
-
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar; 92(1):57-63.